Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Moderate Buy” from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given an average recommendation of “Moderate Buy” by the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $22.80.

Several research analysts recently issued reports on ZVRA shares. Cantor Fitzgerald lowered their target price on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Friday, January 9th. HC Wainwright set a $26.00 target price on shares of Zevra Therapeutics in a research report on Tuesday, December 30th. Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. CWM LLC raised its stake in Zevra Therapeutics by 399.5% during the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after buying an additional 2,297 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Zevra Therapeutics by 30.0% during the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after buying an additional 1,280 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after acquiring an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares in the last quarter. Finally, Creative Planning bought a new position in shares of Zevra Therapeutics during the 2nd quarter worth approximately $92,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $9.00 on Friday. The company has a quick ratio of 8.57, a current ratio of 8.62 and a debt-to-equity ratio of 0.46. The stock has a market cap of $506.68 million, a PE ratio of 19.15 and a beta of 1.08. Zevra Therapeutics has a 12-month low of $6.19 and a 12-month high of $13.16. The business has a 50-day simple moving average of $8.64 and a two-hundred day simple moving average of $9.50.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The company had revenue of $26.06 million during the quarter, compared to the consensus estimate of $26.64 million. Analysts anticipate that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.